Cadrenal Therapeutics (CVKD) Capital Expenditures (2022 - 2025)

Cadrenal Therapeutics (CVKD) posted Capital Expenditures of $1853.0 for Q3 2025, down 43.0% sequentially from $3251.0 in Q1 2025.

Cadrenal Therapeutics (CVKD) Capital Expenditures (2022 - 2025) Analysis & Trends

Cadrenal Therapeutics has reported Capital Expenditures for 3 years, with the latest figure at $1853.0 in Q3 2025.

Quarterly Capital Expenditures changed N/A year-over-year to $1853.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $5104.0 (changed N/A YoY) and the FY2025 annual result came in at $5104.0, down 21.92% from the prior year.
Capital Expenditures retreated to $1853.0 in Q3 2025 per CVKD's latest filing, from $3251.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $3251.0 in Q1 2025 and troughed at $1.0 in Q4 2022.
A 3-year average of $1276.5 and a median of $927.0 in 2022 frame the typical range for Capital Expenditures.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Cadrenal Therapeutics	4.59 Mn	2.19 Mn	-	-

Download Data